Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | NAAA | Q02083 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6379981 | 1.00 | TSHR (0.48) | TSHRCA1CA2CA9NAAA | |
| SCHEMBL25622617 | 1.00 | TSHR (0.48) | TSHRCA1CA2CA9NAAA | |
| SCHEMBL12013298 | 1.00 | TSHR (0.48) | TSHRCA1CA2CA9NAAA | |
| SCHEMBL30388469 | 1.00 | TSHR (0.48) | TSHRCA1CA2CA9NAAA | |
| SCHEMBL2076848 | 0.98 | TSHR (0.50) | TSHRCA1CA2CA9NAAA | |
| SCHEMBL24773083 | 0.95 | TSHR (0.44) | TSHRCA1CA2CA9NAAA | |
| SCHEMBL27032384 | 0.95 | TSHR (0.44) | TSHRCA1CA2CA9NAAA | |
| SCHEMBL29198550 | 0.95 | L3MBTL1 (0.47) | TSHRCA1CA2CA9NAAA | |
| SCHEMBL2568738 | 0.94 | L3MBTL1 (0.49) | TSHRCA1CA2CA9NAAA | |
| SCHEMBL20133100 | 0.90 | L3MBTL1 (0.49) | TSHRCA1CA2CA9NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12202829-B2 | Heterocyclic compound | FIMECS, INC. (JP) | 2025-01-21 | — | — | US | disclosed |
| US-20240246992-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | SERVIER LAB (FR) | 2024-07-25 | — | — | US | disclosed |
| EP-4308570-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | Les Laboratoires Servier (FR) | 2024-01-24 | — | — | EP | disclosed |
| CN-117425661-A | Macrocyclic LRRK2 kinase inhibitors | 法国施维雅药厂 | 2024-01-19 | — | — | CN | disclosed |
| US-20230242529-A1 | HETEROCYCLIC COMPOUND | FIMECS, INC. (JP) | 2023-08-03 | — | — | US | disclosed |
| EP-3609889-B1 | SMALL MOLECULES | UNIV DUNDEE (GB) | 2023-07-05 | — | — | EP | disclosed |
| EP-3609889-B1 | SMALL MOLECULES | UNIV DUNDEE (GB) | 2023-07-05 | — | — | EP | disclosed |
| US-11639354-B2 | Heterocyclic compound | FIMECS, INC. (JP) | 2023-05-02 | — | — | US | disclosed |
| US-20220402935-A1 | HETEROCYCLIC COMPOUND | FIMECS, INC. (JP) | 2022-12-22 | — | — | US | disclosed |
| WO-2022194976-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2022-09-22 | — | — | WO | disclosed |
| US-20220127257-A1 | SMALL MOLECULES | UNIVERSITY OF DUNDEE (GB) | 2022-04-28 | — | — | US | disclosed |
| US-11261179-B2 | Small molecules | UNIVERSITY OF DUNDEE (GB) | 2022-03-01 | — | — | US | disclosed |
| US-20210179614-A1 | HETEROCYCLIC COMPOUND | FIMECS, INC. (JP) | 2021-06-17 | — | — | US | disclosed |
| EP-3831811-A1 | HETEROCYCLIC COMPOUND | Fimecs, Inc. (JP) | 2021-06-09 | — | — | EP | disclosed |
| US-20210163469-A1 | SMALL MOLECULES | UNIVERSITY OF DUNDEE (GB) | 2021-06-03 | — | — | US | disclosed |
| US-20210163469-A1 | SMALL MOLECULES | UNIVERSITY OF DUNDEE (GB) | 2021-06-03 | — | — | US | disclosed |
| WO-2021020586-A1 | HETEROCYCLIC COMPOUND | ファイメクス株式会社 | 2021-02-04 | — | — | WO | disclosed |
| WO-2021020585-A1 | HETEROCYCLIC COMPOUND | ファイメクス株式会社 | 2021-02-04 | — | — | WO | disclosed |
| WO-2020027225-A1 | HETEROCYCLIC COMPOUND | ファイメクス株式会社 | 2020-02-06 | — | — | WO | disclosed |
| EP-2476678-A1 | SUBSTITUTED CARBONYL COMPOUNDS | Ube Industries, Ltd. (JP) | 2012-07-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242529-A1 | HETEROCYCLIC COMPOUND | XIAP, BIRC5, BIRC3 | TSHR 4767/4885CA1 2393/4885CA2 3598/4885 |
| US-20240246992-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | LRRK2, PARK7, PINK1 | TSHR 3780/4885CA1 4825/4885CA2 4681/4885 |
| US-20220127257-A1 | SMALL MOLECULES | ADRM1, MDM2, UBE2B | TSHR 3941/4885CA1 4441/4885CA2 4811/4885 |
| US-11639354-B2 | Heterocyclic compound | XIAP, BIRC5, BIRC3 | TSHR 4767/4885CA1 2393/4885CA2 3598/4885 |
| US-20220402935-A1 | HETEROCYCLIC COMPOUND | IRAK1, IRAK2, IRAK4 | TSHR 2793/4885CA1 4846/4885CA2 4392/4885 |
| US-11261179-B2 | Small molecules | ADRM1, MDM2, UBE2B | TSHR 3941/4885CA1 4441/4885CA2 4811/4885 |
| US-12202829-B2 | Heterocyclic compound | XIAP, BIRC5, BIRC3 | TSHR 4767/4885CA1 2393/4885CA2 3598/4885 |
| US-20210179614-A1 | HETEROCYCLIC COMPOUND | XIAP, BIRC5, BIRC3 | TSHR 4767/4885CA1 2393/4885CA2 3598/4885 |
| US-20210163469-A1 | SMALL MOLECULES | ADRM1, MDM2, UBE2B | TSHR 3941/4885CA1 4441/4885CA2 4811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.